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Gliomas account for more than 50% of all brain 
tumors and are by far the most common primary brain 
tumor in adults, and they are characterized by dismal 
prognoses, with glioblastoma representing the ultimate 
grade of malignancy [1]. The current standardized protocol 
to combat malignant gliomas includes maximal surgical 
resection followed by radiotherapy and temozolomide-
based chemotherapy [2]. This standardized protocol had 
enabled the 5-year survival of glioblastoma patients to be 
increased from 2 to 10% [2]. However, malignant gliomas 
continue to have dismal prognoses, and this result is 
mainly due to two biological characteristics: i) malignant 
gliomas diffusely invade distant brain tissue through 
multiple single migrating cells, which limits the benefit 
of surgical resection; and ii) these migrating glioma cells 
resist pro-apoptotic stimuli, including conventional radio- 
and chemotherapy [1]. 
Reducing the levels of malignant glioma cell motility 
can restore glioma cell sensitivity to pro-apoptotic stimuli, 
and antimigratory compounds should therefore be added 
to conventional radio- and/or chemotherapy to restore 
certain levels of apoptotic sensitivity in glioma cells [1]. 
A growing body of work suggests that cellular 
migration and invasion in cancer cells in general and 
glioma cells in particular are facilitated by ion channels 
and transporters [3]. Glioma cells appear to shrink their 
cell volume to fit into the narrow extracellular spaces 
available and invade the brain parenchyma [3]. These 
features include the secretion of Cl- and K+ through ion 
channels localized to lipid raft domains on invadipodia 
and water passively flowing through water channels or 
aquaporins [3]. In addition, the interplay between Na+-
K+-Cl- cotransporters and Na+/K+ ATPase lead to the 
active accumulation of K+ and Cl-, establishing a gradient 
for KCl efflux [3]. Pharmacological inhibition of large-
conductance calcium-activated potassium channels or 
chloride channels impairs glioma cell migration and 
limits tumor progression in experimental models [3]. One 
Cl- channel inhibitor, TM-601, a synthetic version of the 
peptide chlorotoxin, a small 36 amino acid neurotoxin 
isolated from the venom of the giant yellow Israeli 
scorpion Leiurus quinquestriatus, covalently linked to 
iodine 131 has completed Phase I and II clinical trials for 
the treatment of high-grade gliomas through repeated local 
intracavitary administrations [3]. An important number of 
studies have also reported the involvement of potassium 
channels in cancer progression. The largest family of 
potassium channels is the voltage-dependent potassium 
(Kv) channels. In this group, Kv1.3 and Kv1.5 channels 
modulate the proliferation of different mammalian cells, 
are involved in Ca2+ signaling and cell volume and have 
been analyzed in a number of cancer cell types [4]. The 
levels of expression of Kv1.5 and Kv1.3 channel subtypes 
discriminate between various glioma groups, and a clear 
differential expression of Kv1.5 is observed according 
to malignancy grade [5]. In addition, it has been shown 
that compared with normal cells, several human cancers 
have high mitochondrial membrane potential and low 
expression of the Kv1.5 channel, which both contribute to 
the apoptotic resistance of cancer cells, including gliomas 
[6]. Closing K+ channels or decreasing their expression 
in cancer cells results in an increase in intracellular K+ 
concentration, which in turn increases the tonic inhibition 
that cytosolic K+ exerts on caspases. As a result, Kv1.5 
gene transfer directly activates apoptosis in apoptotic-
resistant non-small lung cancer cells [6]. In addition, the 
functional inhibition of all Kv channels with 4-amino-
pyridine limits dichloroacetate-induced apoptosis by 
38% in glioblastoma cells, suggesting that although the 
majority of apoptosis in dichloroacetate-treated cells is 
a direct result of efflux of proapoptotic mediators from 
cancer cells, the secondary effects on Kv channels also 
play important roles [6].
Kv10.1 is virtually absent from normal cells outside 
the central nervous system and is frequently expressed 
in tumors, in which ectopic expression occurs in 70% 
of human cancers [7]. The targeted inhibition of Kv10.1 
expression in cancer cells decreases their proliferation rate 
[7]. 
Several compounds already used in clinics could 
therefore be added to the conventional treatments used 
to combat malignant gliomas. Imipramine (Tofranil®), 
for example, is a well-known tricyclic antidepressant that 
binds to the intracellular Kv10.1 pocket and consequently 
inhibits its current [7]. Imipramine has already been 
demonstrated to reduce the proliferation, inhibit the PI3K/
Akt/mTOR signaling and induce autophagic cell death in 
human glioma cells [8]. Citalopram (Cipramil®), which 
is a selective serotonin reuptake inhibitor used for its 
antidepressive activity, acts on Kv1.5 currents as an open-
channel blocker. 
Because both imipramine and citalopram have been 
commonly used to treat depression, which commonly 
occurs in glioma patients, it would be interesting to Oncotarget 2012; 3:  516-517 517 www.impactjournals.com/oncotarget
conduct large epidemiological studies to investigate the 
actual benefit that these two drugs would provide for 
malignant glioma patients when delivered during their 
glioma treatment. Such large-scale epidemiological 
studies have recently revealed the actual benefit provided 
by digoxin, a Na+/K+ ATPase inhibitor used to treat heart 
failure, in prostate cancer patients treated for both prostate 
cancer and heart failure [9].
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